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Abstract 
Metastasis accounts for most of the deaths from breast cancer and the preference of 
invasive breast cancer metastasising to bone has been widely reported. However, the 
biological basis of breast cancer osteotropism is not fully understood. This paper provides, 
for the first time, an integrative, systematic review of evidence of molecular factors that have 
functional roles in the homing of metastatic breast cancer to the bone.  
Pubmed, Web of Science and EBSCOhost were searched using keywords and synonyms 
for molecular, metastasis, breast cancer and bone to identify articles published between 
January 2004 and August 2016. 4,491 potentially relevant citations were retrieved. 63  
articles met the inclusion criteria, which were primary studies reporting evidence of 
molecular factors that have functional roles in predisposing breast cancer bone metastasis in 
vivo.12 of those 63  articles that additionally met quality criteria were included in the review. 
Extracted data were tabulated and key findings that indicated biological mechanisms 
involved in breast cancer metastasis to bone were synthesised. 
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15 proteins expressed by breast cancer cells were identified as factors that mediate breast 
cancer bone metastasis: ICAM-1, cadherin-11, osteoactivin, bone sialoprotein, CCN3, IL-11, 
CCL2, CITED2, CXCR4, CTGF, OPN, CX3CR1, TWIST1, adrenomedullin and Enpp1.  
Upregulation or overexpression of one or more of them by breast cancer cells resulted in 
increased breast cancer metastasis to bone in vivo, except for CCL2 where bone-metastatic 
cells showed a reduced expression of this factor.  All factors identified, here expressed by 
breast cancer cells, are proteins that are normally expressed in the bone microenvironment 
and linked to physiologic bone functions.  All have a functional role in one of more of the 
following: cell proliferation and differentiation, bone mineralization and remodeling, cell 
adhesion and/or chemokine signaling. Six of them (cadherin-11, ICAM-1, OPN, CX3CR1, 
CCN3 and osteoactivin) have a reported function in cell adhesion and another eight (CCN3, 
osteoactivin, Enpp1, IL-11, CTGF, TWIST1, adrenomedullin and CITED2) are reported to be 
involved in cell proliferation and differentiation. 
This review collates and synthesises published evidence to increase our understanding of 
the biology of breast cancer osteomimicry in the development of bone metastasis. Findings 
of this review suggest that changes in expression of proteins in breast cancer cells that 
confer ostemimicry facilitate homing to bone to enable the development of bone metastasis.  
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Highlights 
• 15 proteins were identified as factors that promote breast cancer bone metastasis 
• Expression of these factors by breast cancer cells mediate osteotropic metastasis 
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• All factors identified are proteins that are normally expressed in the bone 
microenvironment 
• Breast cancer cell protein expression conferring ostemimicry facilitates osteotropic 
metastasis 
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Introduction 
Paget suggested that cancer cells are more likely to metastasize to a tissue that has the 
necessary components to support their growth, just as a seed would only grow in soil in 
which it can thrive [1]. This concept implies that cancer cells migrate to environments that 
are biologically favourable for colonisation in terms of growth factor production, receptor 
expression and other stromal characteristics, such as tissue origin. If this ‘seed and soil’ 
theory were always true one would expect that cancers in paired organs, like breast and 
kidney, would commonly metastasise to the contralateral organ. However, clinical evidence 
indicates that metastases rarely form in a contralateral paired organ. Furthermore, there is a 
98% chance that a breast cancer in the contralateral breast is due to a second, unrelated 
primary tumour [2].  
Ewing proposed, in contrast, that metastatic site specificity was purely mechanical; the first 
organ that tumour cells passed via blood circulation was the most likely site of metastasis 
owing to their physical entrapment there [3], as in the example of breast cancer metastases 
forming in the lungs. However, a large volume of blood from breast tissue also passes 
through the heart and spleen and breast cancer metastases rarely form in these organs [4]. 
Evidently, beyond the anatomical exposure to cancer cells, there seems to be a requirement 
for host-tumour compatibility and specific interaction for metastasis to occur. Hence Paget’s 
theory of related biological factors is, on balance, more favoured [5]. 
Bone is the commonest and often the earliest site of distant metastasis in breast cancer [6]; 
50% of individuals newly diagnosed with advanced breast cancer have bone metastases, 
compared to 30%, 26% and 7% with liver, lung, brain metastases, respectively [7]. About 
70% of women who die from breast cancer have bone metastases [8], which is where the 
majority of the tumour burden resides at the time of death [2].  
Breast cancer metastases characteristically cause osteolytic lesions, though osteoblastic 
tumours are found in 25% of cases [2]. There is a growing body of evidence that breast 
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cancer cells interact with bone stroma facilitating the process of metastasis [9]. For example, 
breast cancer cells secrete parathyroid hormone related peptide (PTHrP), which stimulates 
osteoblasts to produce RANKL. This in turn activates osteoclasts, which create osteolytic 
lesions, and consequently release growth factors stimulating further growth of the breast 
cancer cells that produce more PTHrP; hence a vicious cycle of positive feedback develops 
[9].  
Osteoclast resorption of the bone has been described as a key characteristic that creates a 
favourable environment for tumour growth. During resorption, osteoclasts secrete proteolytic 
enzymes that degrade the bone matrix and release abundant growth factors, cytokines and 
chemokines, all of which attract circulating tumour cells and support their growth [10]. 
Bussard and colleagues [11] suggested that the continuous bone turnover, together with the 
resultant release of chemotactic and trophic factors, could explain site specificity of bone 
metastasis in most cancers, including breast cancer. However, despite such metastatic 
favourability, bone metastases are very rare in some other common solid tumours, such as 
colorectal cancers [7]. This suggests that beyond the growth promoting environment in bone, 
a significant level of specific interaction is required between cancer cells and bone tissue for 
bone metastases to establish successfully. 
A systematic search of relevant databases for review papers concerning breast cancer 
metastasis to bone identified those focusing on the bone as a common site of metastasis for 
many cancers [11-13] and factors involved in breast cancer metastasis to different host 
organs [6,14]. One review that specifically evaluated factors involved in breast 
cancer metastasis to the bone was found [8]; however, no systematic reviews were 
identified. Therefore, herein, for the first time, we report an integrative, systematic review of 
molecular factors that are shown to have functional roles in homing of metastatic breast 
cancer to the bone. 
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Method 
Literature Search 
A systematic search of articles published in English between January 2004 and September 
2016 was conducted in the electronic databases Pubmed®, Web of Science™ and 
EBSCOhost using keywords and synonyms for molecular, metastasis, breast cancer and 
bone to search ‘all terms’. Boolean operators and truncations of keywords were employed to 
both expand and restrict the search.  Search expansion was performed using citation 
chaining in Web of Science™ and snowballing of reference lists of articles that met inclusion 
criteria. Using this method only one article published prior 2004 was identified that met the 
inclusion criteria for this review. 
 
Inclusion and exclusion criteria 
Studies that reported primary research findings about molecular factors that have a 
functional role in breast cancer bone metastasis were included in this review. Included 
studies were also deemed to have been ethically conducted, for example ethical approval 
was reported in the study, and met defined quality criteria, as follows. Included studies were 
designed prospectively with a focus on bone as a metastatic site from breast cancer. Studies 
entirely carried out in vitro without in vivo testing were excluded in order to ensure that 
findings included in the review considered the role of the tumour microenvironment. Studies 
using bone tropic models that specifically demonstrated osteotropic effects of specific gene 
products were included. This was because the review aimed to identify evidence about gene 
products that exerted osteotropic effects in breast cancer. The same genes may have 
additional roles in metastasis, including enabling metastasis to develop in tissues other than 
bone, but those effects were not the focus of this study, so data about additional putative 
roles were not extracted as part of this review. Studies that focused on assessing 
experimental techniques, clinical data, or therapeutic testing were also excluded. The 
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inclusion and exclusion process is depicted in an adapted PRISMA flow chart adapted from 
Moher et al [15] (Figure 1).                                                                                                                                  
Exclusion process 
Initially citations were screened by OA at the level of the title and then abstract by OA and 
VL for relevance using parameters set by the inclusion and exclusion criteria. Citations that 
met or potentially met inclusion criteria at the level of the title and abstract were obtained in 
full text for further assessment against the inclusion and exclusion criteria. Potentially 
relevant sources were independently reviewed in full by OA and VL for internal validity. In 
addition, full texts of all studies included in the review were assessed by OA and SB for 
eligibility against the inclusion criteria.  
Quality appraisal 
Studies obtained in full text that met the inclusion criteria were assessed for quality by OA 
and SB using a checklist for critiquing scientific research described by Kuyper [16]. Studies 
were assessed to identify whether the following criteria were appropriate and reliable, and 
clearly reported: title, study aims, study design and method (e.g. in vivo, cell lines, animal 
model), and reporting of results. Details of the quality appraisal for each included study are 
shown in Table 1. Authors' conclusions were also appraised to assess whether they 
reflected the findings of the study and whether any limitations of the study were identified 
within the publications reviewed.  Studies that met the quality criteria described above were 
included in the review. The strength of evidence presented by the studies was also assessed 
in order to judge their significance in contributing to the review and thus identify the strengths 
and limitations of the review (Table 1). 
Data extraction 
Data were independently extracted and tabulated by OA and SB in order to aggregate, sort, 
compare and integrate findings [17]. Extracted data were author and publication date; 
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functional factors identified; wild type function of molecular factor(s) (if known); main findings 
from each study; and interpretation of study findings (Table 2). 
 
Integrative synthesis 
The wildtype functions of factors that were found to be associated with breast cancer cells 
preferentially metastasising to bone tissue were analyzed to consider putative molecular 
mechanisms that facilitate breast cancer cells metastasising to bone tissue. From the 
aggregated data extracted from the studies reviewed, functional factors were integrated by 
grouping into categories according to their primary wildtype function. The categories were 
further analysed as a whole (akin to data synthesis) by constructing a diagram of wildtype 
function grouping (Figure 2).  
 
Results                                                                                                                                                               
Retrieval and exclusion process 
The search results and exclusion process is illustrated in a PRISMA flow-diagram (Figure 1). 
From 4,491 citations initially retrieved, after rigorous exclusion, 63 full-text articles were 
assessed for relevance, of which 11 reported primary research that fully met inclusion 
criteria for the review. For example, potentially relevant studies that were excluded from the 
review reported roles in the development of lung metastasis, but did not demonstrate the 
preferential formation of metastases in bone tissue. An additional study published prior to 
2004, which was one of those pioneering the use of in vivo selection to develop bone 
seeking breast cancer clones and gene profiling of the cells [18], was included in the review 
due to its seminal relevance.   
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Fig.1 PRISMA flow-diagram of search results and exclusion process, after Moher et al [15] 
 
Quality appraisal 
Quality appraisal confirmed that all studies included in the review stated clear aims and were 
designed prospectively. All included both in vitro and in vivo approaches using established 
breast cancer cells lines to identify factors associated with the formation of breast cancer 
colonies in bone tissue of inoculated mice, Table 1 and references therein. 
All studies described the use of appropriate and rigorous controls. Control methods were 
carefully assessed to ensure clear the distinction between experimental samples and control 
samples. In most of the studies reviewed, the controls were breast cancer cell lines that had 
poor affinity to metastasize to the bone, or high affinity to metastasize to tissue other than 
bone.  
All studies reported evidence of functional roles for specific molecular factors in the homing 
of breast cancer cells to bone tissue. Nine of the studies reported robust evidence classified 
as ‘strong’ or ‘moderate’, Table 1; they consistently demonstrated correlation between 
expression of specific proteins and the development of bone metastasis using a variety of 
techniques and experimental models.  
Findings from functional studies  
Overall, 15 factors that were associated with breast cancer cells homing to bone tissue were 
reported in the reviewed studies, Table 2 and references therein. Eleven studies reported 
factors that were over-expressed in clones of bone-homing breast cancer cell lines, while 
one study [23] reported a factor (CCL2) that was associated with increased bone metastasis 
when it was down-regulated. Findings were mapped onto a diagram by function, illustrating 
factors and possible molecular mechanisms involved in bone metastasis, Figure 2.                                                                                
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Intercellular adhesion molecule-1 (ICAM-1 or CD5) and cadherin-11 (OB (osteoblast)-
cadherin) were highly overexpressed in both human (MDA-MB-231BO) and murine 
(4T1E/M3) bone metastasizing cancer cells [21,22]. Rose et al [20] reported a correlation 
between endogenous osteoactivin overexpression and the formation of bone lesions in 
multiple cancer cell lines (4T1 cells, its selected bone metastatic population, 590, 592, 593, 
606 BM2 and non-bone metastatic 67NR and 66cl4). Increase in bone metastases in 
immunocompetent mice inoculated with cancer cells (66cl4) bearing exogenously expressed 
osteoactivin was also shown. CITED2 (CREB-binding protein (CBP)/p300 interacting 
transactivator with glutamate (E) and aspartate (D) tail 2) was expressed at high levels in 
sublines of mouse NT2.5 cells that had high bone metastatic potential compared to those 
that had low bone metastatic potential; in addition, knockdown of CITED2 resulted in a 
reduction in bone metastasis [24].  
The expression of chemokine receptor CX3CR1 was significantly increased in cancer cells 
that promote breast cancer bone metastasis in vivo (MDA-MB-231), compared to expression 
levels in cells (MDA-MB-436) that have a weak affinity to metastasize to bone [26]. 
Exogenous overexpression of CX3CR1 in a breast cancer cell line with weak affinity to form 
bone metastasis resulted in a 3-fold increase in bone metastatic tendency. Furthermore, 
introduction of CX3CR1 positive cells into mice null for its binding partner, fractalkine, 
resulted in a significant reduction in bone, but not adrenal, metastases.  
 
Kang et al [18] reported a 4-fold overexpression of CXCR4 in selected bone metastatic 
clones of MDA-MB-231 compared to the parent population, which appeared to have a 
synergistic effect with other co-expressed osteogenic genes (interleukin 11, osteopontin 
(OPN) and connective tissue-derived growth factor (CTGF)) on the formation of bone 
metastasis.    
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A relationship between exogenous overexpression in breast cancer cell lines and the ability 
of the cell line to form bone lesions in vivo was also reported. Zhang et al [19] exogenously 
overexpressed bone sialoprotein (BSP) in breast cancer cells that exclusively formed brain 
lesions in vivo (MDA-MB-231-BR), and found overexpression of BSP resulted in 100% of the 
metastatic lesions forming in bone, and not brain, tissue. Expression of CCN3 (also known 
as nephroblastoma overexpressed (NOV)) in breast cancer cells was associated with 
increased bone metastasis [25]. This indicated a functional role, which was investigated by 
transfecting CCN3 into a weakly bone metastatic cancer cell line (66cl4), which doubled the 
bone affinity of this cell line when inoculated into mice. Siclari et al (2014) [29] reported that 
when adrenomedullin was over-expressed five-fold by MDA-MB-231 cells and inoculated 
into immunodeficient mice, they formed osteolytic bone metastases more rapidly than 
untransfected cells. Moreover, cells over-expressing adrenomedullin formed larger tumours 
when injected into mammary fat pads.  Expression of TWIST1 has also been reported to 
enhance the ability of an osteotropic subclone of MDA-MB-231 cells to form osteolytic 
lesions [28]. A greater number of micrometastases were established, radiographically 
detectable lesions were were 50% larger than those formed by mock-transfected cells, and 
more extensive bone destruction was seen. Suppression of TWIST1 abolished the effect. 
One factor expressed in breast cancer cells was reported to have an inhibitory role in the 
formation of bone metastatic lesions. CCL2 (chemokine C-C ligand 2, also known as 
monocyte chemo-attractant protein 1 – MCP-1) expression was shown to be down regulated 
in bone-specific cancer cells (4T1E/M3) and its overexpression reduced the bone metastatic 
potential of the cancer cells [23]. Another factor appeared to have an osteolytic function. Lau 
et al. [27] reported higher levels of Enpp1 (ectoenzyme ectonucleotide 
pyrophosphatase/phosphodiesterase I) expression in bone seeking human and murine 
cancer cell lines (MDA-MB-231/MDA-MB-468 and NT2.5, respectively). MDA-MB-231 cells 
transfected with Enpp1 had an increased rate of destruction/loss of bone density, compared 
to non-transfected cells. 
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Discussion 
Here we present, for the first time, a systematic review of molecular factors that have 
putative roles in the homing of breast cancer cells to bone. This is a novel method for 
reviewing primary research from molecular biology experiments, and involves conducting a 
systematic search, applying pre-defined inclusion and exclusion criteria, using standard 
criteria to appraise the quality of the findings, and systematically sorting findings. The 
method used in this review has been adapted from established systematic review methods 
used to address medical, health and social science research questions [30-32]. A systematic 
approach to the review enabled secondary analysis of extracted findings as an integrated 
data set. It also facilitated independent review of published findings by members of the 
research team (akin to a process of internal peer review) following a pre-determined, 
standardized method, which we argue increases the validity and reliability of data synthesis. 
This review describes fifteen proteins that were found to be associated with breast cancer 
cells having an affinity to metastasise to bone, which was dependent on their expression 
levels. The wildtype function of these proteins includes cell adhesion and motility, osteoblast 
proliferation and differentiation, mineralisation of bone extracellular matrix, and chemokine 
activity. These factors demonstrated preferential and potent bone tropic function. It is worth 
noting that this finding does not exclude functional roles in the development of metastasis to 
other tissue types and the factors described in this review may also have roles in the 
formation of metastases in tissue sites additional to bone. 
 Six of the fifteen molecular factors identified here have a reported function in cell adhesion 
(cadherin-11, ICAM-1, OPN, CX3CR1, CCN3 and osteoactivin, Figure 2) and all were shown 
to promote bone metastasis when overexpressed in breast cancer cells. Cadherin-11 is a 
calcium dependent cell adhesion protein particularly expressed in osteoblasts [33]. ICAM-1 
is a transmembrane structural protein, but can also exist in soluble form in plasma as 
sICAM-1. It is abundantly expressed on the surface membrane of leukocytes and endothelial 
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cells where it exerts its primary function in adhesion of leukocytes to the vascular 
endothelium, but its expression can also be induced in other cells during inflammatory 
processes [34]. ICAM-1 is also expressed on osteoblast and osteoclast precursor cells in the 
bone microenvironment. It mediates osteoclastogenesis and subsequent bone resorption by 
facilitating osteoblast RANK receptor and osteoclast RANKL ligand leading to osteoclast 
formation [35]. Osteopontin (OPN) has many reported functions, amongst them is osteoclast 
adhesion to bone matrix [36,37]. CX3CR1, a chemokine receptor, is involved in leukocyte 
adhesion and migration during the immune response [38]. The secretory protein CCN3 
found in bone extracellular matrix also functions in cell adhesion [25,39]. Osteoactivin, a 
transmembrane protein found on osteoblasts and osteoclasts plays a regulatory role in 
endothelial cell adhesion [40]. 
Eight of the fifteen factors identified in this review (CCN3, osteoactivin, Enpp1, IL-11, CTGF, 
CITED 2 and TWIST1, adrenomedullin, Figure 2) are reported to be involved in cell 
proliferation and differentiation. CCN3 [39], along with transmembrane proteins osteoactivin 
[40] and Enpp1 [41], have wildtype functions in osteoblast differentiation. Osteoactivin is also 
involved with osteoclast formation [40] and Enpp1 also generates pyrophosphate, which is a 
source of phosphate for bone mineralization, found to be involved in pathologic calcification 
of non-bone tissues [41]. IL-11 is involved in osteoclast formation from bone marrow 
progenitor cells [42], and CTGF in osteoblast formation; both are responsive to transforming 
growth factor beta (TGF-β) signaling [18]. CITED2 is a transcriptional co-activator that 
positively regulates TGF-β signaling and is activated by hypoxia inducible factor 1α (HIF-1α) 
[43]. In addition to increased expression of the extracellular matrix (ECM) protein CCN3 and 
mineralizing protein Enpp1 in bone seeking cells, this review also found bone seeking 
behavior by cells exogenously overexpressing the non-collagenous ECM glycoprotein BSP 
[44,45]. TWIST1 is a transcription factor that regulates cell motility and tissue reorganization 
during embryogenesis [46]. It is reactivated in many cancers where it is involved in epithelial-
mesenchymal transition (EMT) facilitating cancer intravasation and metastasis and in 
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avoidance of senescence and apoptosis [46,47]. Adrenomedullin expression is induced by 
hypoxia. It has complex and widespread homeostatic function including bronchodilation, 
vasodilation, angiogenesis, lymphangiogenesis, hormone secretion and is involved in 
inducing apoptosis and cell proliferation, including osteoblast proliferation [48]. 
 
 
Fig.2 Functional roles of identified factors and possible molecular mechanisms involved in 
bone metastasis 
Most published evidence regarding molecular factors with functional roles in breast cancer 
bone metastases formation identifies cell adhesion, cell differentiation and extracellular 
matrix proteins, consistent with the findings outlined above. However, this review also 
identified putative evidence for the role of chemokine signaling when co-expressed with 
other factors (Figure 2). CCL-2 overexpression reduced bone metastatic potential, however, 
there was still some level of bone metastasis recorded, signifying that other contributing 
factors may be involved in this process [23]. CCL2, a chemokine, is a strong chemotactic 
agent for monocytes, and is expressed in a wide variety of tissues. It has putative roles in 
both macrophage-facilitated angiogenesis and tumour growth inhibition [49]. CX3CR1 is a G-
protein coupled chemokine receptor that is found abundantly in osteoblasts and its ligand, 
CX3CL1 (or fraktalkine), is produced by bone marrow stromal cells [26,50]. CXCR4 is a 
chemokine receptor involved in both bone marrow homing and extravasation [18, 51]. 
Osteopontin is a multifunctional adhesion factor with lymphokine function that stimulates 
osteoclast adhesion to bone matrix [18, 52].  
 
A striking observation about most of the factors identified in this review is that their wildtype 
pattern of expression and function is in the bone microenvironment maintaining normal bone 
physiology. It appears that some breast cancer cells are able to mimic osteogenic cells by 
switching on the expression of osteogenic genes [53]. The intrinsic bone regulating 
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characteristics of healthy breast cells in breast tissue development [54] and lactation [55] 
might confer such osteomimicry in malignant breast cells. In addition to osteomimicry in 
breast cancer cells that form bone metastases, there is evidence of osteomimicry in other 
osteotropic cancers, for example prostate [56] and lung cancers [57]. This suggests a role 
for factors in the tumour microenvironment that is common in osteotropic cancers.  
Osteomimicry is thought to promote both homing of cancer cells to bone tissue and their 
survival in the bone microenvironment [58], which might also explain why these cells 
metastasise to the bone in preference to the contralateral organ, or other remote organs and 
tissues. The gene products described herein could be classified using Nguyen and 
Massague’s classification of ‘metastasis virulence’ genes [59]. Proteins expressed by 
metastasis virulence genes are proposed to direct selective colonization of secondary sites 
by exerting functions, such as capillary adhesion, extravasation and organ specific 
colonization [59]. The review suggests that Paget’s ‘seed and soil’ theory of cancer cells 
forming metastatic colonies in microenvironments that are favourable to their growth [1] 
holds true.   
Strengths and limitations of the review 
We have described the methods we used to conduct a comprehensive, systematic search 
strategy in an attempt to retrieve all relevant literature accessible via electronic databases 
since 2004 and associated snowballing and citation chaining. A pre-defined, standardized 
method of inclusion, exclusion, data extraction and analysis were used to identify integrate 
and synthesise findings of the review, which provides transparency in reporting, and we 
believe adds validity and reliability to conducting a literature review. 
All of the reviewed studies investigated osteotropism of breast/mammary cancer cell lines in 
vivo using a murine model of metastasis, which enabled modeling within the context of 
tumour microenvironments within whole organisms. All studies either reported that ethical 
permission had been obtained or described work that indicated it was conducted in an 
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ethical manner. However, Zhang et al [19], while stating that their study was approved by 
their Institutional Animal Care and Use Committee (University of Texas Health Center at San 
Antonio, USA) and was performed in accordance with NIH Guide for the Care and Use of 
Laboratory Animals, describe how tumour bearing animals became crippled and suffered 
bone fractures, which raises cause for concern.  
Studies on human breast cancer cells used immunodeficient (athymic nude, neu-N and 
SCID) mice to prevent the rejection and immunologic killing of the inoculated human cells by 
the murine immune system, while those using murine mammary tumour cells employed 
immunocompetent (BALB/c mice) mice. Each approach has its strengths and limitations. 
While the use of immunodeficient mice allows the study of metastasis of human breast 
cancer cells in a non-human host, it does so in the absence of immune response factors that 
themselves might be functionally important to metastasis. The use of immunocompetent 
mice addresses that issue, but murine mammary tumours differ fundamentally from human 
breast cancer in many aspects of their metastasis. In almost all studies reviewed here, highly 
artificial techniques were used to create circulating breast cancer cells, which were 
introduced into the mice by either intracardiac, tail vein or intratibial injection, thus modeling, 
at best, only the late stages of metastasis, once the cancer cells are already blood-borne, or 
lodged within bone. Only Takahashi et al [23] attempted subcutaneous implantation, and 
their study resulted in relatively weak evidence of bone metastasis-specific factors. Croset et 
al [28] performed xenograft experiments, injecting cancer cells into the mammary fat pad, 
but only in order to assess primary tumour growth. In this study, metastasis was achieved 
through tail artery injection.  
There is also the issue that cell lines themselves are limited in their ability to reflect the 
complexities of clinical cancer biology. It is interesting that a limited range of cancer cell lines 
were used in the studies reported here. MDA-MB-231 were employed in all eight studies that 
used human breast cancer cell lines, sometimes in combination with one or more other of 
MDA-MB-468 and MDA-MB-436. In those studies that used murine mammary cancer cells, 
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4/6 studies employed 4T1 cells and their metastatic variants. This resulted in highly 
homogeneous tumour formation and the limitation that data are being derived from a very 
narrow model which, potentially, may not accurately reflect the clinical situation. Whilst 
useful for investigating functional gene expression, this does not reflect the highly 
heterogeneous profile of most metastatic human breast cancers. In addition, bone 
metastases develop more commonly from estrogen receptor (ER) positive than ER negative 
breast cancers [60]; however several cell lines used in the reviewed studies lacked ER 
expression, for example MDA-MB-231 and 4T1 [61]. It would therefore be preferable for 
studies investigating the bone metastatic properties of breast cancer cells to employ ER 
positive cell lines, such as the human MCF-7 cell line. There are, therefore, many obvious 
limitations in these well used and accepted model systems. Overall, these methodological 
factors need to be taken into consideration when interpreting research findings, as they may 
cause experimental artefacts that do not accurately model natural processes.  
Different experimental approaches were used in the studies reviewed, including genomics, 
transcriptomics and proteomics, and findings from studies that used multiple techniques to 
explore the functional role of a given molecular factor might be regarded as providing more 
convincing evidence. In several studies, microarray analysis of highly bone metastatic breast 
cancer clones identified tens to hundreds of genes that were overexpressed or 
underexpressed [18,23,24], however further in vitro and in vivo testing was only reported for 
1 – 4 of these genes, and the criterion for selecting these genes was generally not described 
or was vague. Such selection of subsets of samples creates a potential for bias, which we 
recognise might be reflected in the review. 
 
Clinical implications  
Bone metastases from breast cancer cause significant morbidity and mortality. Currently, 
there are no diagnostic techniques that enable reliable detection of bone micrometastases at 
18 
 
the time of diagnosis. Instead breast cancer bone metastases are commonly diagnosed 
following presentation of a symptom, such as pain. Bone targeted agents, bisphosphonates 
[62,63] and denosumab (Xgeva®, Amgen) [63,64], are effective for reducing pain and 
delaying time to the first skeletal related event (SRE) (pathological fracture, spinal cord 
compression, bone radiation or bone surgery) in people with advanced breast cancer 
[65,66]. Serious adverse events that lead to discontinuation of bone targeted therapies 
include hypocalcaemia, impaired renal function and osteonecrosis of the jaw [67]. Best 
supportive care and palliative symptom control also have a role in reducing the risk of SRE 
and reducing pain in cases where bone targeted agents are contraindicated, for example 
impaired renal function [68]. Although interventions for treating bone metastases are 
effective in managing symptoms and delaying SRE, the majority of bone-targeted therapy 
trials have not been shown to improve overall survival of people with bone metastatic breast 
cancer [65].  
An eminently preferable strategy to palliating symptoms of bone metastases or delaying 
SRE would be to prevent the development of bone metastases in the first instance. One 
approach might be to use adjuvant treatment targeting factors that promote breast cancer 
cells metastasising to the bone prior to the formation of bone metastasis, which has been 
explored in mouse models in several studies reported here [21,24,26]. However, much work 
is yet to be done to achieve this outcome in humans, since it requires a robust body of 
evidence to indicate the role of a molecular factor expressed in early breast carcinogenesis 
that later confers bone metastatic character, development of molecular diagnostic 
techniques to determine which tumours present a risk of forming bone metastasis, and 
subsequent development of effective targeted therapies that are clinically tolerable. Clinical 
correlation between the presence of the functional factors identified in this review in primary 
tumours in patients and either poor clinical outcome or, in some instances, specifically the 
presence of bone metastases, provides evidence that they may represent promising targets 
for such further endeavor. Some instances of such evidence are summarized below. 
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In the study by Jamieson-Gladney et al [26] identified in this review, in addition to the animal 
model work described previously, the authors also performed immunohistochemistry to 
detect CX3CR1 on tissue arrays of human breast cancer and normal breast tissue samples. 
They reported a low level of CX3CR1immunopositivity in normal breast and an increase in 
intensity and distribution of immunopositivity in breast cancers, a finding that is consistent 
with the authors’ previous work on prostate cancer [69]. Here, in addition, bone marrow was 
shown to contain soluble CX3CL1/fractalkine, which is released from bone marrow cells 
upon androgen stimulation, thus suggesting a potential role in bone tropism. Similarly, in the 
study by Lau et al (2013) [27] included in this review, the authors assessed human clinical 
samples alongside their animal studies. Comparing both mRNA levels and Enpp1 
immunolabelling of clinical samples, they demonstrated that Enpp1 was overexpressed in 
primary breast cancer compared to normal breast epithelium, and that the highest levels 
were observed in breast cancer metastases to bone. The same group [24] took a similar 
approach to their work highlighting CITED2 as potentially relevant to breast cancer 
osteotropsim. Again, in addition to the animal experiments discussed in this review, the 
authors examined clinical samples of primary invasive ductal carcinoma and bone 
metastasis samples and found levels of CITED2 mRNA to be elevated in both in comparison 
to normal breast epithelium. Moreover, levels in bone metastases were significantly higher 
than in primary tumours. 
Bone sialoprotein has been detected in primary breast cancers [70,71] and clearly 
associated with development of bone metastases [72], which are also BSP-positive [73], and 
poor survival [74]. Osteopontin overexpression is also established as being associated with 
metastasis, although not specifically to bone, in many types of cancer [reviewed by 75,76]. 
Differential osteopontin expression has been detected in breast cancer samples [77] and 
plasma osteopontin levels have been clinically correlated with the presence of bone 
metastases and with survival rates in prostate cancer patients [78].  TWIST1 expression by 
primary breast cancers is associated with more clinically aggressive disease and poor 
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survival [79] and is detectable in breast cancer cells that remain in the bone marrow 
following chemotherapy [80]. Adrenomedullin is expressed by many type of cancer [reviewed 
by 81]. Around 80% of breast cancers express adrenomedullin and high levels in the primary 
tumour and in the plasma predict lymph node metastases; a role in bone metastasis has 
been proposed [82]. IL-11 expression in primary breast cancer correlates with subsequent 
development of bone metastases [83]. CXCR4 has been implicated in the development of 
bone metastases in patients with neuroblastoma [84] and prostate cancer [85].  
ICAM1 levels have been measured in the cytosol of breast cancer and benign breast tissue 
samples [86] and has been reported to induce a more invasive phenotype in breast cancer 
[87], but an association with bone metastasis in clinical studies has not specifically been 
explored. Osteoactivin is overexpressed in glioblastoma multiforme and is associated with 
poor clinical outcome and has been proposed as a potential molecular therapeutic target 
[88], although, again, association with bone metastasis specifically has not been reported. 
Cadherin-11 expression is well established as being associated with cancer cell 
invasiveness and epithelial mesenchymal transition (EMT). A recent meta-analysis of human 
cancer microarray datasets revealed that cadherin-11 is increased in breast ductal 
carcinoma in situ and breast cancer in comparison to normal breast epithelium, and is 
elevated in the stroma surrounding breast cancers compared to normal stroma [89]. Its 
association with metastatic competence has not been explored specifically.  CCL2 has been 
detected in primary breast cancer samples [90], and ER-negative tumours have been 
reported to exhibit high levels of CCL2 expression [91]. In pancreatic cancer, patients with 
high serum CCL2 levels had a better prognosis than those with low levels [92], consistent 
with the findings reported in this review [23] that it is negatively associated with metastatatic 
competence. 
CCN3 has diverse functional roles, which are context dependent. This complexity is reflected 
in conflicting reports of its significance in cancer biology. While CCN3 has been reported to 
exert growth-suppressive effects in several cancer types, paradoxically, it has also been 
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shown to have a pro-migration and pro-metastatic role in melanoma [93] and Ewing’s 
sarcoma [94] and high levels predict poor prognosis in prostate cancer [95], osteosarcoma 
[96] and renal cell cancer [97]. In breast cancer, reports have also been contradictory, with 
some reporting an association with good prognosis [98] and others reporting association with 
resistance to endocrine therapy [99]. In the study by Ouellet et al [25] reported in this review, 
in addition to the animal experiments, clinical samples of bone metastases from breast 
cancer were examined and strong CCN3 immunopositivity of tumour cells was seen in 50% 
of cases. Other studies have demonstrated high CCN3 positivity in bone metastases in 
comparison to metastases at other sites [100]. CTGF, also known as CCN2, is another 
member of the CCN family. Its presence in oral squamous cell carcinomas has been shown 
to be associated with local invasion of the mandible [101]. In hepatocellular carcinoma, 
intratumoral  immunopositivity of the primary tumour biopsy for CTGF was predictive of bone 
metastases and, interestingly,  combining intratumoral CTGF with IL-11, discussed 
previously, was an independent risk factor for bone metastases development [102]. In breast 
cancer, it is one of four genes (one of the others was osteopontin, discussed previously), 
that were identified as being overexpressed in bone metastases compared to disseminated 
tumour cells in the bone marrow that had not formed tumours [103] and was found to be 
overexpressed in primary breast cancers that had metastasised to bone as well as in the 
tumor cells of breast cancer bone metastases when compared to normal breast tissue [104]. 
 
Implications for future research 
Further investigation is needed to elucidate molecular factors that have a functional role in 
enabling breast cancer cells to metastasise to bone tissue. Further experiments are 
specifically required to increase understanding of molecular interactions, signaling pathways, 
both upstream and downstream, of proteins identified in this review, which have putative 
functional roles in mechanisms of breast cancer bone metastasis. Prospective, longitudinal 
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epidemiological studies, which include both exomic (sequencing the entire complement of 
exons) and proteomic analysis of tumour biopsies excised from cohorts of patients 
diagnosed with primary stage breast cancer, might identify additional important factors that 
have a functional role in the metastasis of breast cancer to bone. 
 
Conclusions 
We are still some distance from developing diagnostic techniques to identify primary breast 
cancers that have potential to metastasise to bone tissue, and specifically targeting such 
cells before the development of clinically apparent metastatic tumours. An important step in 
developing these techniques is increasing our understanding of the molecular mechanisms 
involved in these processes. In order to inform the development of future research on the 
topic, this systematic review integrates recent literature to identify molecular factors that 
have putative functional roles in the development of breast cancer bone metastases. 
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All studies were prospective, included both in vitro and in vivo approaches, and employed appropriate controls for each experiment. Statistical 
analysis, where relevant, was performed appropriately. The title of each paper accurately reflected content. 
Author and 
publication 
date 
Are study aims  
clearly 
apparent? 
Experimental 
approaches 
What cell lines are 
used? 
What animal 
model is used? 
Strengths and limitations of evidence presented 
Kang et al., 
2003 [18] 
Yes 
To identify 
genes that 
mediate breast 
cancer 
metastases to 
bone 
In vivo cell 
selection and 
gene profiling 
Bone- and adrenal-
metastasis specific 
human breast 
cancer cell clones 
derived from 
parental MDA-MB-
231 cell line 
Intracardiac 
injection of 
human cancer 
cell line into 
athymic nude 
mice 
 
Rigorous selection of bone-specific human breast 
cancer cells and demonstration of significant over 
expression of several factors (IL-11, CTGF, CXCR4, 
OPN) working in synergy to promote bone metastasis 
in vivo. Functionality demonstrated by transfection of 
genes into parental cell line. Specificity confirmed by 
comparison of bone-specific with adrenal-specific 
clones. MMP-1 was also highlighted as of interest in 
this study but only preliminary data, indicated its 
functional significance, alone or with other factors, in 
enhancing bone metastatic ability. 
Strong evidence for function in bone-specific 
metastasis 
Zhang et al., 
2004 [19] 
 
Yes 
To investigate 
the role of bone 
sialoprotein 
(BSP) in breast 
cancer 
metastasis to 
bone 
Cell 
transfection 
and in vivo 
metastasis 
Bone- and brain-
seeking  human 
breast cancer cell 
clones derived 
from parental 
MDA-MB-231 cell 
line 
Intracardiac 
injection of 
human cancer 
cell line into 
athymic nude 
mice 
 
Expression of BSP in a brain-seeking human breast 
cancer cell clone resulted in 100% successful 
establishment of bone metastases in vivo. 
Strong evidence for function in bone-specific 
metastasis 
Rose et al., 
2007 [20] 
 
Yes 
To demonstrate 
that osteoactivin 
promotes bone 
metastasis in 
breast cancer 
In vivo 
cancer cell 
selection, 
gene 
profiling, cell 
transfection 
and in vivo 
metastasis 
Bone-seeking 
clones of mouse 
mammary cancer 
4T1 
Intracardiac 
injection into 
immunocompe
tent BALB/c 
mice 
 
Consistent demonstration of osteoactivin in multiple 
bone-seeking clones, confirmed by several 
complimentary techniques. Expression of osteoactivin 
by a non-bone metastasising clone imparted bone 
metastastic ability. However, the use of murine cell 
lines, albeit in an immunocompetent host, limits the 
relevance of the findings to human cancer. 
Moderate evidence for function in bone-specific 
metastasis 
Tamura et al., 
2008 [21] 
 
Yes 
To evaluate the 
role of cadherin-
11 in homing of 
In vivo 
selection, 
protein 
analysis, cell 
Parental, bone-
seeking and brain-
seeking clones of 
human breast 
Intracardiac 
injection of 
human cancer 
cell line into 
The significant expression of cadherin-11 in bone 
seeking cell lines, reduction in recorded bone 
metastasis with its inactivation and failure of expected 
lung metastases in cadherin-11 bearing cells in an 
breast cancer 
cells to bone 
transfection 
and in vivo 
metastasis 
cancer cell line 
MDA-MB-231  
athymic nude 
mice 
 
animal model that usually produces lung metastases 
all provide strong evidence for a functional role in 
promoting breast cancer bone metastasis. 
Strong evidence for function in bone-specific 
metastasis 
Takahashi et 
al., 2008 [22] 
 
Yes 
To investigate 
the function of 
ICAM-1 in highly 
bone metastatic 
breast cancer 
cells 
In vivo 
selection, 
gene 
profiling, in 
vivo 
metastasis, 
in vitro 
functional 
testing 
Mouse mammary 
cancer 4T1 and a 
highly metastatic 
variant 4T1E/M3 
Tail vein 
injection into 
immunocompe
tent BALB/c 
mice 
ICAM-1 and beta 2 integrin expression in bone 
seeking cells was demonstrated using multiple 
techniques identifying their expression at both 
genomic and transcriptomic level.  Functionality of 
ICAM-1 was explored, but not beta 2 integrin, and this 
is a limitation of the study. In discussion, it is 
mentioned that anti-ICAM-1 and anti-beta 2 integrin 
antibodies had no inhibitory effect on 4T1E/M3 
adhesion to bone marrow derived endothelial cells, 
but data is not presented. Further, 4T1E/M3 cells were 
not exclusively metastatic to bone and showed a high 
level of metastasis to lung, as well as, less commonly, 
other sites. A further limitation of the study is the use 
of murine cells, albeit in an immunocompetent host. 
Moderate evidence for ICAM-1function in bone-
specific metastasis 
Takahashi et 
al., 2009 [23] 
 
Yes 
To examine the 
impact of CCL2 
in regulating 
breast cancer 
bone metastasis 
In vivo cell 
selection, 
gene 
profiling, in 
vivo 
metastasis, 
in vitro 
functional 
testing 
Highly metastatic 
variant 4T1E/M3 of 
mouse mammary 
cancer 4T1 
Intravenous 
and 
subcutaneous 
injection into 
immunocompe
tetent BALB/c 
mice 
While bone metastasis reduced with CCL2 expression 
in a bone specific clone, there was still bone 
metastasis in 36% of cases compared to 0% of the 
non-bone seeking parental cells, despite expressing 
CCL2 at similar levels.  Moreover, a further limitation 
of the study is the use of murine cells, albeit in an 
immunocompetent host. 
Weak evidence for function in bone specific 
metastasis. 
Lau et al., 
2010 [24] 
 
Yes 
To evaluate the 
role of CITED2 
in promoting 
osteotropism in 
breast cancer 
In vivo 
selection, 
gene 
profiling, 
gene 
knockdown 
and in vivo 
metastasis 
neu-expressing 
mammary tumor 
cell line NT2.5 and 
subclones with 
differing metastatic 
capability 
Human bone 
metastatic MDA-
MB-231 and MDA-
MB-468, and non-
metastatic 11-24 
HME and MCF-
Intracardiac 
injection of 
murine and 
human cancer 
cells into neu-
N mice 
 
CITED2 expression was clearly correlated with 
increased bone metastatic potential in both murine 
and human cell lines using several different 
techniques. 
Strong evidence for function in bone specific 
metastasis. 
10A 
Ouellet et al., 
2011 [25] 
Yes 
To evaluate the 
role of CCN3 in 
breast cancer 
metastasis to 
bone 
In vivo 
selection, 
protein 
analysis, cell 
transfection 
and in vivo 
metastasis, 
in vitro 
functional 
testing 
Mouse mammary 
cancer 4T1   
Weakly bone 
metastatic mouse 
mammary cancer 
cell line 66cl4 
Intracardiac 
injection into 
immunocompe
tent BALB/c 
mice 
 
Functionality of CCN3 was demonstrated by showing 
that CCN3 expression increased bone metastatic 
tendency in a cell line that is naturally poorly 
metastatic. However, in addition to the use of murine 
cell lines, albeit in immunocompetent animals, no 
report of sites of metastasis other than bone were 
mentioned, making it impossible to assess the bone 
specificity for the effect of this factor 
Weak evidence for function in bone specific 
metastasis. 
Jamieson-
Gladney et al., 
2011 [26] 
 
Yes 
To investigate 
the role of 
fractalkine and 
its receptor 
CX3CR1 in bone 
metastasis from 
breast cancer 
Cell 
transfection 
and in vivo 
metastasis 
Human breast 
cancer cell lines 
MDA-MB-231, 
MDA-MB-436 
Intracardiac 
injection into 
SCID mice or 
control non-
immune 
compromised 
mice; 
fractakine null 
transgenic 
mice 
Functional role of CX3CR1 is demonstrated by 
knockdown experiments. Bone specificity is 
demonstrated by comparison with adrenal 
metastases. Some evidence of bone metastasis was 
seen in mice null for CX3CR1 binding partner, 
fractalkine, suggesting that other factors, not 
considered in the study, may be implicated  
Moderate evidence for function in bone specific 
metastasis. 
 Lau et al., 
2013 [27] 
Yes 
To evaluate the 
role of Enpp1 in 
breast cancer 
bone metastasis 
In vivo 
selection, 
gene 
profiling, 
protein 
analysis, cell 
transfection 
and in vivo 
metastasis 
HER-2/neu—
expressing mouse 
mammary tumour 
cell line, NT2.5 
Human breast 
cancer cell lines 
MDA-MB-231, 
MDA-MB-468 
intracardiac 
and intra-tibial 
injection into 
athymic nude 
mice 
While the authors state that Enpp1 was identified in 
their previous study Lau et al (2009) as being of 
special interest, it does not actually appear as a gene 
of interest in that paper. 
Enpp1 expression was increased in bone seeking 
murine and human breast cancer cells and in human 
breast cancer bone metastases in comparison to 
primary tumours and normal breast epithelium. 
Expression of Enpp1 by MDA-MB-231 cells resulted in 
no greater rate of bone metastasis, but more rapid 
bone destruction.  
Moderate evidence for function in bone specific 
metastasis. 
 
Croset et al., 
2014 [28] 
Yes 
To explore the 
functions of 
TWIST1 in 
breast cancer 
bone metastasis 
Cell 
transfection, 
in vivo 
inoculation, 
in vitro 
functional 
testing 
MDA-MB-231/BO2, 
a bone metastatic 
clone of human 
breast cancer cell 
line.  
Human MCF-7 and 
mouse 4T1 breast 
Tail artery 
injection into  
nude mice. 
Assessment of 
primary tumour 
growth was 
achieved by 
MDA-MB-231/BO2 cells demonstrated earlier and 
significantly larger osteolytic bone metastasis 
compared to control when TWIST1 was exogenously 
expressed in them. TWIST1 was, however, not found 
to be inherently expressed in MDA-MB-231/BO2 and 
other bone metastatic clones. 
Weak evidence for function in bone specific 
  
 
cancer cell lines xenograft into 
the mammary 
fat pad.  
metastasis. 
Siclari et al., 
2014 [29] 
Yes 
To evaluate the 
role of 
adrenomedullin 
in enhancing 
bone metastasis 
in breast cancer 
and explore its 
potential as a 
therapeutic 
target for 
treatment of 
bone metastasis 
cell 
transfection 
and in vivo 
metastasis, 
ex vivo co-
culture and 
functional 
analysis 
Multiple breast 
cancer cell lines 
were tested for 
adrenomedullin 
expression.  
MDA-MB-231 
clones were used 
for gene 
transfection and 
mice inoculation 
Intracardiac 
injection into 
athymic nude 
mice 
 
Clear demonstration of a functional role for 
adrenomedullin  in enhancing osteolytic metastasis. 
Adrenomedullin was found to be expressed in normal 
tissues (including breast, kidney and prostate) and 
lung metastases, suggesting that adrenomedullin may 
not only contribute to specific bone tropism. 
Adrenomedullin is more likely contribute to growth of 
already formed bone metastasesrather than playing a 
causal role. 
Moderate evidence for function in bone specific 
metastasis. 
 
 
 Table 2 Summary of data extraction 
Author and 
publication 
date 
Functional factor(s) 
identified  
Wild type function 
of  
molecular 
factor(s) 
Functional 
classification of 
molecular 
factor(s) 
Summary of main study findings Brief interpretation of study 
findings 
Kang et al., 
2003 [18] 
IL 11 
 
 
 
 
Connective  tissue 
growth factor CTGF 
(CCN2) 
 
 
 
 
CXCR4  
 
 
 
osteoclast 
formation; further 
activated by 
TGFbeta 
 
Osteoblast 
differentiation 
and proliferation, 
angiogenesis; 
further activated 
by TGFbeta 
 
a chemokine 
receptor involved 
in chemotaxis, 
cell proliferation 
Cytokine / 
growth factor 
 
 
 
Cytokine / 
growth factor 
 
 
 
 
 
Chemokine 
receptor 
 
 
In vivo selection of bone- and adrenal-metastasis 
specific human breast cancer cell clones derived 
from MDA-MB-231 and determination of bone-
specific, and not adrenal-specific, metastasis gene 
signature. 
 
Confirmation that parental and bone-metastatic 
subclones conform to a previously established poor 
prognosis gene signature, and no evidence that 
acquisition of bone-homing activity is associated with 
increased expression of these genes. Further 
analysis revealed distinct gene signatures 
associated with clones that selectively metastasise 
to bone and to adrenal gland, and bone-metastasis-
associated genes distinct from the previously 
established poor prognosis gene signature. IL11, 
Investigations reveal a gene 
profile, already present in the 
parental cell population, which, 
when superimposed on an 
already metastasis-associated 
gene signature, specifically 
enhances metastasis to bone. 
IL11, CTGF, CXCR4 and OPN 
are convincingly shown to work 
synergistically.  These genes 
encode proteins associated 
with angiogenesis, tumour cell 
invasion, recruitment of 
osteoclasts suggesting that 
their action contributes to a 
microenvironment favouring 
 Osteopontin (OPN) 
(early T lymphocyte 
activation gene 1 
eta1, secreted 
phosphoprotein 1 
spp1, bone 
sialoprotein 1) 
 
 
 
 
 
 
 
 
 
Multiple 
functions. 
Stimulates 
osteoclast 
adhesion to bone 
matrix. 
Lymphokine. 
 
 
 
Extracellular 
matrix protein / 
cytokine 
 
 
 
 
CTGF, CXCR4 and MMP-1 were identified as the 
most highly overexpressed in the bone-metastasis 
populations. 
 
Parental MDA-MB-231 cells transfected to express 
high levels of IL11 required co-expression of 
osteopontin (OPN) before enhanced bone 
metastasis was observed. CXCR4 when expressed 
alone resulted in limited enhanced bone metastatic 
ability. Increased expression of CTGF alone did not. 
Triple transfectants expressing OPN and IL11 with 
either CXCR4 or CTGF showed dramatic enhanced 
bone metastatic ability. Preliminary data only, not 
shown, was suggestive of MMP-1 alone or in 
combination with IL-11 and OPN enhancing bone 
metastasis. 
 
Populations of cells which over expressed the IL11, 
CTGF, CXCR4, MMP1, OPN bone metastasis gene 
signature were both found to be present in the 
original parental MDA-MB-231population and to 
exhibit enhanced ability to metastasise to bone. 
Cells expressing this multi-gene signature were 
establishment of metastases. 
Cell populations highly 
metastatic to adrenal medulla 
do not share this signature, 
suggesting a basis for tissue 
specificity. 
  
found to be enriched in the bone-metastasis selected 
clones derived from MDA-MB-231 
 
Zhang et al., 
2004 [19] 
 
 
Bone sialoprotein 
(BSP, bone 
sialoprotein II) 
Bone 
homeostasis 
Extracellular 
matrix protein 
Exclusively bone- and brain-seeking clones derived 
from MDA-231 cells were established. Upon 
transfection with BSP, the brain-seeking clones 
formed bone metastases. Transfection with vector 
only had no effect. Bone lesions, detected by 
radiological examination, were also examined using 
standard histological techniques, and in situ 
hybridisation and immunohistochemistry to localise 
BSP. High levels of BSP mRNA and protein were 
localised in the bone metastases. 
Convincing evidence for the 
role of BSP in establishment of 
bone metastasis was shown in 
this study as its expression 
caused significant bone 
metastasis in a completely 
non-bone seeking cell line 
Rose et al., 
2007 [20] 
 
 
Osteoactivin Involved in 
osteoblast 
differentiation 
and osteoclast 
formation 
Cell adhesion 
protein  
Sub-populations of 4T1 cancer cells showing 
enhanced metastasis to bone were selected. These 
cells were more motile and more invasive than the 
parental cell line or cells selected to be tumorigenic 
and non-metastatic, or metastatic to lung but not 
bone. 
 
Gene expression profiling using microarray identified 
a range of 12 genes with elevated expression and 4 
with lower expression in strongly bone-metastasising 
Compelling evidence is 
presented that osteoactivin 
expression is necessary and 
sufficient for MMP-3 
expression and also 
associated with enhanced 
invasiveness, probably in 
conjunction with other 
mediators, in selected bone-
seeking cell populations. 
cell populations in comparison to parental or weakly 
bone metastatic populations. Of these, osteoactivin 
was chosen for further study because it has been 
identified as being associated with increased 
invasion and motility in glioma. It was confirmed that 
the strongly bone-metastasising population 
expressed high levels of osteoactivin in comparison 
to parental or weakly bone metatstatic cells. 
Furthermore, knock-down of osteoactivin resulted in 
a reduction in invasive ability of cells. Levels of 
MMP-3 in various cell populations correlated with 
osteoactivin and bone metastasis potential, 
consistent with literature reports that osteoactivin 
induces MMP-3 expression. Osteoactivin-positive 
cells showed enhanced metastasis to bone in 
comparison to osteoactivin negative controls and 
bone tumour cells showed increased levels of both 
osteoactivin and MMP-3 in these studies. 
 
Tamura et al., 
2008 [21] 
 
 
Cadherin-11 
(CDH11) 
Cell adhesion 
molecule, 
mediates cell 
adhesion through 
homophilic 
interactions. 
Expressed by 
bone marrow 
cells and 
osteoblasts. 
Cell adhesion 
protein  
Cadherin-11 expression was markedly increased in 
bone-seeking clones of MDA-MB-231 cells in 
comparison to the parental cell line or to brain-
seeking clones. 
 
MDA-MB-231 cells stably transfected with intact 
cadeherin-11 and an inactive variant that is unable 
to form homophilic interactions. The cells expressing 
intact cadherin-11 showed increased bone 
metastases in an animal model compared to the 
parental cell line.  Cells expressing inactive 
cadherin-11 showed reduced bone metastasis. No 
difference in ability to metastasise to lung was noted, 
thus indicating that cadherin-11 is specifically 
involved in establishment of bone metastases. 
These observations were supported by evidence 
that cadherin-11- positive cancer cells arrested in 
greater numbers in bone marrow than cells of the 
parental line, and that cells expressing inactive 
cadherin-11 arrested in decreased numbers. When 
co-cultured with a cadherin-11 expressing bone 
stromal cell line, increased migration of the cancer 
cells was observed, and this was not seen in co-
Increased e expression of 
cadherin-11 in bone-seeking 
cell clones, increased bone 
metastasis when cadherin-11 
is expressed and reduction in 
bone metastasis when an 
inactive variant is expressed all 
provide evidence for cadherin-
11 promoting metastasis to 
bone. Evidence is provided 
that this is an organ-specific 
phenomenon as no 
relationship between cadherin-
11 and increased metastasis to 
other sites (brain, lung) is 
observed. Furthermore, 
evidence is provided that the 
mechanism of action is through 
homophilic cell-cell adhesive 
interactions between cadherin-
11 positive cancer cells and 
cadherin-11 positive bone 
stromal cells resulting in 
culture experiments using a non-cadherin-11 
expressing fibroblast cell line. 
Immunohistochemistry revealed that cadherin-11-
positive cancer cells formed homophilic cell-cell 
interactions with bone stromal cells. Moreover, in a 
co-culture system, homophilic interactions between 
cadherin-11 on cancer cells and on mouse 
osteoblastic cells resulted in up-regulation of the 
osteoclastogenic cytokine PTH-rP by the cancer 
cells. 
 
 
increased cancer cell migration 
and up-regulation of the 
osteoclastogenic cytokine 
PTH-rP by the cancer cells. 
Thus, cadherin-11 expression 
by breast cancer cells 
promotes, through homophilic 
interaction with cadherin-11 
expressed on bone stromal 
cells,  cancer cell homing 
specifically to bone, then 
directed migration and 
osteoclastogenesis 
Takahashi et 
al., 2008 [22] 
 
 
ICAM-1 
 
 
 
 
 
 
 
 
 
Cell adhesion 
molecule and 
member of the 
immunoglobulin 
superfamily. 
Mediates cell to 
cell interaction of 
osteoblast and 
osteoclast 
precursor cells in 
Cell adhesion 
protein 
 
 
 
 
 
 
 
 
Rigorous in vivo selection of 4T1E cells was 
performed to develop a cell line with enhanced 
metastasis, 4T1E/M3. The cells, which were highly 
clonal, showed enhanced bone metastasis but 
metastasised to other sites, including liver, spleen, 
heart, and, especially lung. Cells of 4T1E/M3 
proliferated only slightly faster than the parental line, 
but exhibited increased adhesion to both plasticware 
and to bone marrow derived endothelial cells, were 
more motile in a wound healing assay and showed 
Increased ICAM-1 and beta 2 
integrin expression in bone 
seeking cells was 
demonstrated. Further, 
functional significance of 
ICAM-1 was demonstrated by 
the inhibitory action of anti-
ICAM-1 antibody on migration 
and colony formation.  
 
  
 
 
 
osteoclast 
formation, 
leukocyte 
migration in 
inflammation 
 
 
 
 
 
increased anchorage independent proliferation in 
soft agar. They express increased levels of ICAM-1 
and beta 2 integrin and anti-ICAM-1 antibodies 
inhibit their migration and colony formation.  
Takahashi et 
al., 2009 [23] 
 
 
CCL2 (chemokine 
C-C ligand 2, 
monocyte 
chemoattractant 
protein-1, MCP-1) 
Member of the 
CC chemokine 
superfamily. 
Involved in 
mediating 
leukocyte 
migration 
Cytokine / 
growth factor 
Further exploration of the enhanced bone and lung 
metastatic 4T1E/M3 cells established previously by 
this group reveal that CCL2 is much reduced in 
comparison to the parental cell line.  Its restitution 
diminishes the cells metastatic ability to colonise 
bone and lung, reduces their migration and 
anchorage independent growth and downregulates 
expression of ICAM-1. Conversely, knocking down 
CCL2 in the parental cell line renders it more 
metastatic and this is associated with increased 
expression of ICAM-1. Knockdown of ICAM-1 in 
4T1E/M3 cells does not increase CCL2 production, 
but knocking down CCL2 does result in upregulation 
of ICAM-1, suggesting that CCL2 is an upstream 
modulator of ICAM-1 expression.   
In this study, a continuation of 
Takahashi et al (2008), the 
authors further explore 
molecular players responsible 
for enhanced metastatic ability 
of 4T1E/M3 cells in 
comparison to the parental 
cell line. Here, down 
regulation of CCL2 is shown 
to be associated with 
enhanced metastasis to both 
lung and bone, and an 
interesting interaction between 
CCL2 and ICAM-1, identified 
in the previous study as being 
positively associated with 
enhanced metastasis, is 
demonstrated. Further 
evidence is presented that 
CCL2 is an upstream 
modulator of ICAM-1 
expression. 
Lau et al., 
2010 [24] 
 
CITED2 A transcriptional 
co-activator 
involves 
regulation of 
haematopoiesis 
 
Intracellular 
signalling protein 
Expression of a number of genes, including CCL9, 
Ephrin B2, CTGF, and CITED2 was significantly 
over-expressed in highly bone metastatic murine cell 
line (BO6) compared to the poorly bone metastatic 
clones and parent cell line (LI and NT2.5 
respectively) using microarray analysis. CITED2 was 
chosen for further analysis. CITED2 expression was 
significantly increased in bone metastatic human 
breast cancer cell lines (MDA-MB-231 and MDA-MB-
468) compared to non-metastatic ones (11-24 HME 
and MCF-10A) using quantitative PCR analysis and 
levels were elevated in human primary invasive 
breast cancer samples in comparison with normal 
breast epithelium, and elevated in clinical bone 
metastases. 
 
Silencing of CITED2 expression by NT2.5 cells did 
not cause any change in rate of cell proliferation, but 
resulted in reduced bone metastasis. 
Strong evidence was shown 
for CITED2 as expression was 
clearly correlated with 
increased bone metastatic 
potential in both murine and 
human breast cancer cell lines 
using complementary 
approaches. 
Immunocompetent mice were 
used for animal inoculation 
bearing more similitude to 
natural tumour environment. 
Ouellet et al., 
2011 [25]  
 
 
CCN3 
(NOV) 
Matricellular 
protein  that 
regulates 
osteoblast 
differentiation, 
function in cell 
adhesion 
Extracellular 
matrix protein 
 
This study continues from the work of Rose et al 
(2007) in which sub-populations of 4T1 cancer cells 
showing enhanced metastasis to bone were 
selected. Further analysis, reported here, 
demonstrated over-expression of CCN3 in these 
cells in comparison to weakly bone metastatic 
counterparts. A variety of complementary techniques 
were employed, including microarray analysis, 
quantitative PCR, immunoblotting and 
immunofluorescence. 
 
Immunohistochemical staining for CCN3 in human 
breast cancer bone metastasis samples revealed 
that that most (11 out of 14) stained moderately to 
strongly for CCN3 and that CCN3 was also abundant 
in the bone stroma. 
 
Weakly bone metastatic murine breast cancer cell 
line 66cl4 showed doubled tendency to form bone 
metastasis on transfection with CCN3 cDNA.  
 
In vitro, CCN3 was shown to inhibit osteoclast 
differentiation and result in an increased 
Functionality of CCN3 was 
demonstrated by showing that 
CCN3 transfection increased 
bone metastatic tendency in a 
cell line that is naturally poorly 
bone metastatic. However, no 
report of other sites of 
metastasis was given to 
assess bone specificity of 
CCN3.That CCN3 is of 
importance in formation of 
bone metastasis is, however, 
much strengthened by the 
careful and complimentary 
experiments seeking to 
determine functional effects in 
influencing osteoclast 
formation. 
RANKL/OPG ratio. Furthermore, CCN3 could induce 
osteclastogenesis in rRANKL primed cells through 
immobilising Ca2+ ions and induced nfact 1nuclear 
localisation, which is important in octeoclast 
differentiation. Evidence is also presented that CCN3 
induced osteoclast differentiation involves JNK and 
PKC signalling 
Jamieson-
Gladney et al., 
2011 [26] 
 
 
CX3CR1  Chemokine 
receptor. Binds to 
CX3CL1or 
fractalkine (FKN). 
Mediates 
leukocyte 
migration and 
adhesion during 
immune 
response 
 
 
Chemokine 
receptor and 
adhesion 
molecule 
Both normal and malignant human breast biopsies 
were shown to express CX3CR1 by 
immunohistochemistry of tissue microarrays. 
Expression and distribution increased with malignant 
transformation. 
 
Using Western blotting, bone metastatic human 
breast cancer cell line MDA-MB-231 was shown to 
express high levels of CX3CR1while MDA-MB-436 
did not. The CX3CR1 positive cells showed a greater 
propensity to establish bone metastases in an 
animal model than the CX3CR1 negative cells. 
 
FKN-null mice were inoculated with CX3CR11 
expressing MDA-MB-231 cell and over 70% 
reduction in the disseminated tumour cells homing to 
Highly convincing evidence 
that CX3CR1 expressed on 
blood-borne cancer cells is 
recognised by FKN expressed 
on endothelium of bone 
marrow to mediate cancer cell 
homing to bone. 
 
the bone marrow compared to wild type animals. In 
comparison, no difference in metastasis to adrenal 
gland was detected between the two groups.  
 
Elegant experiments examined the effect of 
transfecting poorly bone-metastatic MDA-MB-436 
cells with either fully functional CX3CR1, or one of 
two partially functional mutants. Animal experiments 
then allowed examination of function at different time 
points post-innoculation. Results provided strong 
support for a role of CX3CR1in early adhesion to 
bone marrow endothelium  and overall, CX3CR 
conferred  the cells with 3 times greater ability to 
form bone metastases 
Lau et al., 
2013 [27] 
Enpp1 
Ectoenzyme 
ectonucleotide 
pyrophosphatase / 
phosphodiesterase 
1 
Regulated bone 
mineralization 
and osteoblast 
differentiation; 
modulates insulin 
signalling. 
Regulates 
extracellular PPi 
levels 
Mineralising 
protein 
This study builds on the previous paper from this 
group, Lau et al (2009).Enpp1expression was shown 
to be increased in bone seeking murine (NT2.5) and 
human breast cancer cell population (MDA-MB-
231/MDA-MB-468) using quantitative PCR, western 
blotting and immunohistochemical analysis. Further, 
Enpp1 mRNA and protein were increased in primary 
human breast cancers in comparison to normal 
breast epithelium with highest levels in bone 
Transfection of Enpp1 cDNA 
into MDA-MB-231 cells 
showed no change in the 
occurrence of bone metastasis 
compared to the control as 
parental cells also produce 
bone metastases in all cases, 
though there was increased 
bone destruction and 
metastases. 
Increased expression  of Enpp1 by MDA-MB-231 
cells resulted in more rapid progression of bone 
metastases 
progression of disease 
 
The paper does not investigate 
potential function of Enpp1 in 
establishment or progression 
of bone metastases, but 
putative mechanisms are 
suggested. 
Croset et al., 
2014 [28]  
TWIST1 Involved in 
regulation of 
organogenesis 
and plays 
important role in 
bone formation. A 
key regulator of 
epithelial-
mesenchymal 
transition (EMT) 
in tumour 
progression 
Transcription 
factor 
TWIST1 expression in bone tropic MDA-MB-
231/BO2 caused quicker bone metastasis and 
increased osteolytic lesion when inoculated into 
mice. 
 
Preservation of bone tropism of MDA-MB-231/BO2 
cells was demonstrated with TWIST1 expression as 
no evidence of metastasis was found organs other 
than bone. 
 
Significant reduction in incidence and extent of 
tumour cell colonies in bone marrow was observed 
when miR-10b (induced by TWIST1) was silenced.  
TWIST1 is shown to enhance 
bone metastatic progression in 
breast cancer cells that have 
pre-existing osteotropism. 
Hence a promoter rather than 
an initiator of osteolytic 
metastasis is indicated. 
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(n = 4,484) 
Additional records identified by hand 
searching and citation chaining 
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Records following 
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(n = 250)
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•reviews 
•conference abstracts, 
•experimental models and techniques
• clinical data
• therapeutic investigations 
•studies not relevant to the topic
Full-text articles assessed 
for relevance 
(n = 63)
187 excluded: 
•retrospective studies 
•studies on bone metastasis not specific for breast 
cancer
•studies on breast cancer metastasis not specific 
for the bone 
Critical appraisal of 
articles for quality (n=25)
38 excluded:
•studies conducted only in vitro
•studies using cell lines that were not in vivo
selected
•studies identifying markers without 
demonstrating functional role in colonization
13 excluded
•Studies where cell line later established not to 
be of breast origin
•Low quality studies; that did not clearly show a 
factor’s role in predisposing bone metastasis or 
not focusing on a factor or set of factors 
Articles included for 
review (n = 12)
Fig.1 PRISMA flow-diagram of search results and exclusion process, after Moher et al [15]
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Fig.2 Functional roles of identified factors and possible molecular mechanisms 
involved in bone metastasis
Siclari et al., 
2014 [29] 
Adrenomedullin, AM Widespread 
homeostatic 
function including 
vasodilation, 
angiogenesis, 
hormone 
secretion and cell 
proliferation 
 
Stimulates 
osteoblast 
proliferation 
Signalling 
protein/hormone 
Adrenomedullin expression was positive in majority 
of osteolytic breast cancer cell lines. 
 
Nude mice inoculation of MDA-MB-231 cells with 
fivefold over-expression of adrenomedullin mRNA 
induced significantly increased osteolytic metastasis 
and reduced survival when compared to control or 
parental cells. 
 
RANKL, produced by osteoblasts for osteoclast 
activation, was inhibited with addition of 
adrenomedullin antagonist to ex vivo breast cancer 
cell–bone co-culture model. 
Adrenomedullin, found in 
normal tissue is shown to play 
a role in enhancing osteolytic 
metastasis when over-
expressed in breast cancer 
cells. Its inhibition resulted in 
reduced osteoclast activity due 
to RANKL blockade suggesting 
a potential therapeutic target 
against bone metastasis. 
 
 
 
 
 
 
 
